This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, M. E. Articles by Sahm, D. F. Search for Related Content PubMed PubMed Citation Articles by Jones, M. E. Articles by Sahm, D. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2002, p. 2651-2655, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2651-2655.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Longitudinal Assessment of Antipneumococcal Susceptibility in the United States

Focus Technologies, Inc., 1217 KP Hilversum, The Netherlands,¹ Focus Technologies, Inc., Herndon, Virginia 20171,² Focus Technologies, Inc., Franklin, Tennessee, 37064³

Received 27 June 2001/ Returned for modification 15 October 2001/ Accepted 2 May 2002

The prevalence of antimicrobial resistance among 4,940 U.S. pneumococcal isolates collected during 1999 was as follows: penicillin, 16.2%; amoxicillin-clavulanate, 12.2%; cefuroxime, 28.1%; ceftriaxone, 3.6%; trimethoprim-sulfamethoxazole, 30.3%; azithromycin, 21.4%; levofloxacin, 0.6%; and moxifloxacin, 0.1%. Compared to the previous 1997-1998 study (Jones et al., Antimicrob. Agents Chemother. 44:2645-2652, 2000), increases were noted for resistance to penicillin (3.7%; P < 0.001), amoxicillin-clavulanate (3.9%; P < 0.001), cefuroxime (5.7%; P < 0.001), azithromycin (2.4%; P = 0.014), trimethoprim-sulfamethoxazole (15.4%; P < 0.001), and levofloxacin (0.3%; P = 0.017). Resistance to ceftriaxone (0.1%; P = 0.809) and moxifloxacin (0.03%; P = 0.570) decreased. Concurrently, multidrug resistance increased (P < 0.001) from 6.3% to 11.3%.

This article has been cited by other articles:

• Critchley, I. A., Brown, S. D., Traczewski, M. M., Tillotson, G. S., Janjic, N. (2007). National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance Study. Antimicrob. Agents Chemother. 51: 4382-4389 [Abstract] [Full Text]  
• Sadowy, E., Izdebski, R., Skoczynska, A., Gniadkowski, M., Hryniewicz, W. (2005). High Genetic Diversity of Ciprofloxacin-Nonsusceptible Isolates of Streptococcus pneumoniae in Poland. Antimicrob. Agents Chemother. 49: 2126-2129 [Abstract] [Full Text]  
• Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
• Otani, T., Tanaka, M., Ito, E., Kurosaka, Y., Murakami, Y., Onodera, K., Akasaka, T., Sato, K. (2003). In Vitro and In Vivo Antibacterial Activities of DK-507k, a Novel Fluoroquinolone. Antimicrob. Agents Chemother. 47: 3750-3759 [Abstract] [Full Text]  
• Davies, T. A., Goldschmidt, R., Pfleger, S., Loeloff, M., Bush, K., Sahm, D. F., Evangelista, A. (2003). Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother 52: 168-175 [Abstract] [Full Text]  
• Jones, M. E., Karlowsky, J. A., Blosser-Middleton, R., Critchley, I., Karginova, E., Thornsberry, C., Sahm, D. F. (2003). Reinterpretation of Susceptibility Data Using Current NCCLS Breakpoint Criteria. Antimicrob. Agents Chemother. 47: 830-830 [Full Text]